Molecular Oncology Group, Department of Obstetrics and Gynecology, Medical University of Vienna, Vienna, Austria.
Institute of Pathophysiology and Allergy Research, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, Austria.
Anticancer Res. 2022 Jan;42(1):429-439. doi: 10.21873/anticanres.15501.
BACKGROUND/AIM: Lung cancer is the most prevalent type of cancer globally and small cell lung cancer (SCLC) accounts for only 15% of all cases but exhibits a dismal prognosis. The standard of care of SCLC has not changed for decades and novel biomarkers and novel strategies for patient's care are urgently needed.
The expression of the two potential markers MUC1 and CD147 was evaluated in circulating tumor cells (CTCs) and CTC-derived SCLC cell lines using qRT PCR, western blotting, immunohistochemistry, and ELISA assays.
Both CTCs enriched from patient blood samples by Parsortix isolation technology and SCLC/CTC cell lines exhibited significant expression of MUC1 and CD147. Silencing of MUC1 increased chemosensitivity of an SCLC line to topotecan.
Both markers, MUC1 and CD147, are highly expressed in patient-derived SCLC and SCLC CTC cell lines and show promise as potential biomarkers in SCLC.
背景/目的：肺癌是全球最常见的癌症类型，小细胞肺癌（SCLC）仅占所有病例的 15%，但预后较差。SCLC 的治疗标准几十年来没有改变，因此迫切需要新的生物标志物和新的患者治疗策略。
使用 qRT-PCR、western blot、免疫组化和 ELISA 检测循环肿瘤细胞（CTCs）和 CTC 衍生的 SCLC 细胞系中两种潜在标志物 MUC1 和 CD147 的表达。
通过 Parsortix 分离技术从患者血液样本中富集的 CTCs 和 SCLC/CTC 细胞系均显示出 MUC1 和 CD147 的显著表达。沉默 MUC1 可增加 SCLC 细胞系对拓扑替康的化疗敏感性。
患者来源的 SCLC 和 SCLC CTC 细胞系中均高度表达这两种标志物 MUC1 和 CD147，它们有望成为 SCLC 的潜在生物标志物。
